Skip to content

Apioc Contact Lens Feasibility

Evaluation of the Feasibility of Fitting of Apioc Contact Lenses in Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03688672
Enrollment
50
Registered
2018-09-28
Start date
2018-10-01
Completion date
2020-10-31
Last updated
2022-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ametropia, Astigmatism, Hyperopia, Myopia, Presbyopia

Keywords

contact lens, soft contact lens, feasibility

Brief summary

This clinical trial will document the feasibility of the Apioc lens design by assessing which lens shape parameters yield successful on-eye-fit and movement of the Apioc contact lens design and evaluate the subjectively-reported comfort of the Apioc contact lens design.

Detailed description

This is a one-site, non-dispensing clinical trial using the Apioc contact lens design. This soft contact lens study will determine the feasibility of this design by determining which parameters of the shape of the Apioc Contact Lens design will yield a successful fit across subjects. We will also determine the percentage of subjects who can be successfully fitted with the Apioc Contact Lens Design. Because the feasibility of the lens design may be dependent upon age, a total of 50 subjects (10 subjects each across 5 decades of life) will complete the study. The data will be collected in a single visit for most subjects. A few subjects may be asked to return for a second visit if additional contact lens parameters need to be ordered to achieve a successful fit. The key assessments for this study will be demonstration of feasibility of fit, documentation of movement in all gazes, including translation, and subjective reports of comfort. Subjects will only wear contact lenses while in the office.

Interventions

DEVICEApioc Contact Lens Design

Novel soft contact lens design.

Sponsors

Lentechs, LLC
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

1. Thirty subjects will be at least 40 years of age and no more than 60 years of age. Ten subjects will be at least 18 years of age and no more than 29 years of age. Ten subjects will be at least 30 years of age and no more than 39 years of age. 2. The subject must have ≤ 1.50 D of corneal astigmatism. 3. The subject should have clear, healthy corneas. 4. The subject should have a normal, healthy conjunctiva in both eyes. 5. The subject should be free of active ocular disease. Refractive error and presbyopia are permitted. 6. The subject must provide written informed consent. 7. The subject must appear willing and able to adhere to the instructions set forth in this protocol.

Exclusion criteria

1. No irregular corneal astigmatism is permitted. 2. No pterygia or corneal scarring that would interfere with contact lens wear. 3. No pinguecula or other conjunctival thickness abnormalities are permitted that would interfere with contact lens wear. 4. The subject should not be using any ocular pharmaceutical treatments, including artificial tears in the two weeks prior to the examination.

Design outcomes

Primary

MeasureTime frameDescription
Vertical Movement of Contact Lens in DowngazeAfter 15 minutes of on-eye settlingVertical movement of the contact lens relative to the eye in downgaze in millimeters.

Secondary

MeasureTime frameDescription
Movement of contact lens with blinkAfter 15 minutes of on-eye settlingMovement of contact lens in straight-ahead gaze with a blink in millimeters.
Visual AcuityAfter 15 minutes of on-eye settlinglogMAR visual acuity at 40 cm through the contact lens with distance correction in trial frame over the Apioc contact lens.
Comfort questionnaireAfter 15 minutes of on-eye settlingSubjects will be asked to assess the comfort of each lens by marking an X on a line between 0 and 100.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026